Detail akcie Dainpn Sumi Phar online

Business Summary: Sumitomo Dainippon Pharma Co., Ltd., is a pharmaceutical company. The Company operates in four segments. The Japan segment manufactures and sells medical drugs. The North America segment manufactures, develops, purchases and sells ethical drugs. The China segment manufactures and sells ethical drugs through its consolidated subsidiary. The Other Overseas division is involved in the development of its products in Europe. The Company is also engaged in the manufacture, purchase, sale and supply of food materials and additives, chemical products, veterinary drugs, diagnostic products and inspection services of clinical pathology for animal, the manufacture of extracts, as well as the storage, delivery and clinical inspection of drugs.
Financial Summary: BRIEF: For the six months ended 30 September 2019, Sumitomo Dainippon Pharma Co Ltd revenues increased 2% to Y230.6B. Net income increased 9% to Y30.33B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Eliminations and Corporate segment loss decrease of 61% to Y18.88B, Pharmaceutical business-Northern America segment income increase of 13% to Y62.05B.